Welcome

Update on restricted Cerezyme supply and Cerezyme Emergency Treatment Program (CETP):

Genzyme has informed all parties involved in the treatment of Gaucher disease patients that resupply of Cerezyme has started as of December 2009. The company expects that it can meet anticipated worldwide demand and allow all patients to return to their normal infusion and dosing regimen during the first quarter of 2010. Therefore the CETP is now closed. Patients have been asked to contact their treating physicians for information on the timing and process to re-start their infusion program. The EWGGD has formulated recommendations regarding the restoration of Cerezyme (see article below). Click here to see Genzyme press release

Guidelines for the restart of imiglucerase in patients with Gaucher disease: Recommendations from the European Working Group on Gaucher disease: See publication

A letter to the editor of the Blood Cells, Molecules and Diseases was published on the 18th December 2009 from Professor Timothy Cox, University of Cambridge Department of Medicine: Recommendations for treating patients with Gaucher disease with emerging enzyme products: see publication

Vial Contamination:

You may be aware that there has been recent information in the media regarding 'Particles found in Cerezyme vials', for your information please find a link below to the statement made by the US Food and Drug administration (FDA) on this issue. FDA Statement - 13th November 2009

We encourage you to discuss any concerns you may have with your doctor at your treating centre. 

Call us on 01453 549231 if you are worried or have any further questions